294648-35-4

Basic information

• Product Name: 9H-Purin-6-amine, N-([1,1'-biphenyl]-4-ylmethyl)-2-chloro-9-(1-methylethyl)-
• CAS NO: 294648-35-4
• Molecular Formula: C21H20ClN5
• Molecular Weight: 377.876
• Mol File: 294648-35-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 9H-Purin-6-amine, N-([1,1'-biphenyl]-4-ylmethyl)-2-chloro-9-(1-methylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 9H-Purin-6-amine, N-([1,1'-biphenyl]-4-ylmethyl)-2-chloro-9-(1-methylethyl)-(294648-35-4)
• EPA Substance Registry System: 9H-Purin-6-amine, N-([1,1'-biphenyl]-4-ylmethyl)-2-chloro-9-(1-methylethyl)-(294648-35-4)

Safety Data

• Hazardous Substances Data: 294648-35-4(Hazardous Substances Data)

Upstream product

• 203436-46-8 Biphenyl-4-ylmethyl-(2-chloro-9H-purin-6-yl)-amine 
• 75-30-9 2-iodo-propane 
• 712-76-5 N-(4-phenyl)benzylamine 
• 203436-45-7 2,6-dichloro-9-isopropyl-9H-purine 
• 5451-40-1 2,6 dichloropurine 

Downstream Products

• 294647-05-5 (R)-2-(1-hydroxy-but-2-ylamino)-6-[4-(phenyl)phenylmethylamino]-9-iso-propylpurine 
• 441055-91-0 C₂₇H₃₁N₇O 
• 441055-95-4 C₂₇H₃₃N₇ 
• 294647-29-3 C₂₇H₃₃N₇ 
• 294647-33-9 C₂₇H₃₂N₆O 
• 441055-89-6 C₂₅H₂₉N₇ 
• 441055-80-7 C₂₃H₂₇N₇ 
• 441055-84-1 C₂₄H₂₉N₇ 
• 441055-86-3 C₂₅H₃₁N₇ 
• 294648-89-8 C₂₉H₃₇N₇O₂ 
• 441055-93-2 C₃₅H₃₉N₇O₂ 

Relevant articles and documents

CALCIUM CHANNEL AGONISTS

Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I wherein each bond depicted as " " is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.

Biaryl purine derivatives as potent antiproliferative agents: Inhibitors of cyclin dependent kinases. Part I

The introduction of an aryl ring onto the 4-position of the C-6 benzyl amino group of the Cdk inhibitor roscovitine (2), maintained the potent Cdk inhibition demonstrated by roscovitine (2) as well as greatly improving the antiproliferative activity. A series of C-6 biarylmethylamino derivatives was prepared addressing modifications on the C-6 biaryl rings, N-9 and C-2 positions to provide compounds that displayed potent cytotoxic activity against tumor cell lines. In particular, derivative 21h demonstrated a >750-fold improvement in the growth inhibition of HeLa cells compared to roscovitine (2).

Synthesis and activity of 2,6,9-trisubstituted purines

The preparation of a series of 2,6,9-trisubstituted purines and the structure-activity data for the inhibition of cyclin dependent kinase, CDK2 are presented.